ONCT NASDAQ
Oncternal Therapeutics, Inc.
1W: +0.0%
1M: -24.1%
3M: -57.9%
1Y: -94.6%
3Y: -98.9%
5Y: -99.4%
$0.53
Last traded 2024-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$785K
-47.3% ▼
5Y CAGR: -20.8%
Gross Profit
-$29M
-2309.6% ▼
Operating Income
-$42M
+7.2% ▲
Net Income
-$39M
+9.0% ▲
EPS (Diluted)
$-13.43
+18.6% ▲
EBITDA
$2M
+105.0% ▲
5Y CAGR: +17.3%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $2M | $3M | $4M | $1M | $785K |
| YoY Growth | -3.8% | +39.2% | +27.9% | -65.5% | -47.3% |
| Cost of Revenue | $10M | $12M | $169K | $179K | $30M |
| Gross Profit | -$8M | -$9M | $4M | $1M | -$29M |
| Gross Margin | -318.9% | -255.6% | 96.1% | 88.0% | -3690.2% |
| R&D Expenses | $10M | $13M | $24M | $33M | $30M |
| SG&A Expenses | $7M | $8M | $12M | $13M | $13M |
| Operating Expenses | $15M | $18M | $31M | $45M | $13M |
| Operating Income | -$33M | -$18M | -$31M | -$45M | -$42M |
| Operating Margin | -1365.3% | -519.8% | -726.9% | -3016.6% | -5313.9% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$34M | -$17M | -$31M | -$44M | -$39M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$16M | -$17M | -$31M | -$43M | -$39M |
| Net Margin | -656.2% | -509.9% | -725.4% | -2912.3% | -5029.2% |
| EPS (Diluted) | $-30.81 | $-0.69 | $-1.94 | $-16.50 | $-13.43 |
| EBITDA | -$33M | -$17M | -$31M | -$45M | $2M |
| Shares Outstanding | 516449 | 25M | 16M | 3M | 3M |